Moreover, last year Frassanito et al. demonstrated that BM fibroblasts or cancer-associated fibroblasts (CAFs) from bortezomib resistant patients produce high levels of different growth factors (including IGF-I and TGFß) and protect the MM cells from bortezomib induced apoptosis [192]. The gene discussed is IGF1; the disease is Miyoshi myopathy.